Clinically important response to treatment (short term) · patients with schizophrenia
Haloperidol showed no clear difference in clinically important response to treatment (short term) compared with first‐generation antipsychotics (low certainty).
1 finding from 1 review
Adverse events as N of participants with at least one adverse event objective · patients with schizophrenia
It is very uncertain whether haloperidol changes adverse effects: number of participants with at least one adverse… compared with first‐generation antipsychotics (very low certainty).
1 finding from 1 review
Adverse effects: extrapyramidal side effects: number of participants with at least one extrapyramidal side effect (medium term) · patients with schizophrenia
It is very uncertain whether haloperidol changes adverse effects: extrapyramidal side effects: number of participants… compared with first‐generation antipsychotics (very low certainty).
1 finding from 1 review
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
Haloperidol showed no clear difference in leaving the study early due to any reason as a measure of overall… compared with first‐generation antipsychotics (low certainty).
1 finding from 1 review
Leaving the study early ‐ short term ‐ due to lack of efficacy · patients with schizophrenia
It is very uncertain whether haloperidol changes leaving the study early due to inefficacy of treatment as a measure… compared with first‐generation antipsychotics (very low certainty).
1 finding from 1 review
Leaving the study early ‐ due to adverse effects (short term) · patients with schizophrenia
It is very uncertain whether haloperidol changes leaving the study early due to adverse events as a measure of… compared with first‐generation antipsychotics (very low certainty).
1 finding from 1 review
Number of participants reporting an adverse event · patients with schizophrenia
Haloperidol showed no clear difference in adverse effects: number of participants with at least one adverse… compared with first‐generation antipsychotics (low certainty).
1 finding from 1 review
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
It is very uncertain whether haloperidol changes adverse effects: extrapyramidal side effects: number of participants… compared with first‐generation antipsychotics (very low certainty).
1 finding from 1 review
Response to treatment (medium term) Clinically important response to treatment as defined by each study · patients with schizophrenia
Haloperidol may leads to lower clinically important response to treatment (medium term) compared with first‐generation antipsychotics (low certainty).
1 finding from 1 review
Leaving the study early ‐ medium term ‐ any reason · patients with schizophrenia
It is very uncertain whether haloperidol changes leaving the study early due to any reason as a measure of overall… compared with first‐generation antipsychotics (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with schizophrenia
1 finding from 1 review
Tranquillisation or asleep ‐ not reported · psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Repeated need for tranquillisation ‐ not reported · psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Specific behaviour ‐ agitation · psychosis‐induced aggression or agitation
1 finding from 1 review
Global outcome ‐ not reported · psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects · psychosis‐induced aggression or agitation
HALOPERIDOL may leads to higher adverse effects compared with OTHER ANTIPSYCHOTICS: g. QUETIAPINE (low certainty).
1 finding from 1 review
Economic outcome ‐ not reported · psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Specific behaviour: aggression ‐ important decrease in aggression · people with long‐term aggression in psychosis
HALOPERIDOL leads to lower specific behaviour: aggression ‐ important decrease in aggression compared with OTHER ANTIPSYCHOTICS (high certainty).
1 finding from 1 review
no estimate extracted
83 participants
High
Repeated need for rapid tranquillisation · people with long‐term aggression in psychosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Specific behaviour ‐ threat or injury to self or others average change score (ABS, high = worse) at 2 hours · people with long‐term aggression in psychosis
HALOPERIDOL leads to lower specific behaviours ‐ threat or injury to others/self compared with OTHER ANTIPSYCHOTICS (high certainty).
1 finding from 1 review
no estimate extracted
83 participants
High